Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) CFO David Knox purchased 27,950 shares of Hyperion DeFi stock in a transaction on Wednesday, December 31st. The shares were acquired at an average cost of $3.59 per share, for a total transaction of $100,340.50. Following the completion of the transaction, the chief financial officer owned 327,950 shares of the company’s stock, valued at $1,177,340.50. This represents a 9.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Hyperion DeFi Price Performance
Hyperion DeFi stock opened at $3.96 on Tuesday. The firm has a fifty day moving average of $4.45 and a 200-day moving average of $7.57. Hyperion DeFi, Inc. has a 52-week low of $0.85 and a 52-week high of $17.18. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $32.35 million, a P/E ratio of -0.98 and a beta of 2.69.
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $0.36 million for the quarter. As a group, analysts predict that Hyperion DeFi, Inc. will post -41.6 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on HYPD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Wednesday, October 8th. Chardan Capital set a $7.75 price objective on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Finally, Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.58.
Read Our Latest Stock Analysis on HYPD
About Hyperion DeFi (
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company’s product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
Read more on InsiderTrades.com
